Vanderbilt-Ingram Cancer Center

Dr. Vandana Abramson, M.D.

Claim this profile

Vanderbilt University/Ingram Cancer Center

Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
31 drugs studied

Area of expertise

1Breast Cancer
Global Leader
Vandana Abramson, M.D. has run 14 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER negative
HER2 negative
2Breast Cancer
Vandana Abramson, M.D. has run 9 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER negative
Stage IV

Affiliated Hospitals

Image of trial facility.
Vanderbilt University/Ingram Cancer Center
Image of trial facility.
Vanderbilt Breast Center At One Hundred Oaks

Clinical Trials Vandana Abramson, M.D. is currently running

Image of trial facility.

ZEN-3694 + Pembrolizumab + Chemotherapy

for Breast Cancer

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Immunotherapy with monoclonal antibodies, such as pembrolizumab may help the body's immune system attach the cancer and may interfere with the ability of tumor cells to grow and spread. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Combination therapy with ZEN003694 pembrolizumab immunotherapy and nab-paclitaxel chemotherapy may help shrink or stabilize cancer for longer than chemotherapy alone.
Recruiting1 award Phase 1
Image of trial facility.

Endoxifen

for Breast Cancer

This trial is testing (Z)-endoxifen, a drug that blocks estrogen, in pre-menopausal women with a specific type of breast cancer. The study aims to see if this drug can slow down cancer growth by measuring a marker called Ki-67. Participants will take the drug daily for several months before surgery.
Recruiting1 award Phase 27 criteria

More about Vandana Abramson, M.D.

Clinical Trial Related8 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Vandana Abramson, M.D. has experience with
  • Trastuzumab
  • Pembrolizumab
  • Sacituzumab Govitecan
  • Avelumab
  • Atezolizumab
  • Pertuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Vandana Abramson, M.D. specialize in?
Is Vandana Abramson, M.D. currently recruiting for clinical trials?
Are there any treatments that Vandana Abramson, M.D. has studied deeply?
What is the best way to schedule an appointment with Vandana Abramson, M.D.?
What is the office address of Vandana Abramson, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security